Epimedin B
CAS No. 110623-73-9
Epimedin B ( —— )
Catalog No. M17818 CAS No. 110623-73-9
Epimedin B has potential activity against osteoporosis by stimulating osteoblasts.
Purity : 98%
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 142 | In Stock |
|
10MG | 216 | In Stock |
|
100MG | Get Quote | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameEpimedin B
-
NoteResearch use only, not for human use.
-
Brief DescriptionEpimedin B has potential activity against osteoporosis by stimulating osteoblasts.
-
DescriptionEpimedin B has potential activity against osteoporosis by stimulating osteoblasts.
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorOthers
-
Research AreaOthers-Field
-
Indication——
Chemical Information
-
CAS Number110623-73-9
-
Formula Weight808.78
-
Molecular FormulaC38H48O19
-
Purity98%
-
SolubilityDMSO : 33.33 mg/mL. 41.21 mM;
-
SMILESCC1C(C(C(C(O1)OC2=C(OC3=C(C2=O)C(=CC(=C3CC=C(C)C)OC4C(C(C(C(O4)CO)O)O)O)O)C5=CC=C(C=C5)OC)OC6C(C(C(CO6)O)O)O)O)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Olmutinib
Olmutinib (HM61713, BI-1482694) is a pontent and T790M-specific third-generation EGFR inhibitor for treatment of NSCLC.
-
Tarloxotinib bromide
Tarloxotinib bromide is an irreversible inhibitor of EGFR/HER2.
-
Befotertinib
Befotertinib is an inhibitor of EGFR tyrosine kinase and can be used for studies about EGFR T790M-positive non-small cell lung cancer.